Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000874310 | SCV001016468 | likely benign | Hereditary spastic paraplegia 30; Neuropathy, hereditary sensory, type 2C; Intellectual disability, autosomal dominant 9 | 2024-11-13 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001509204 | SCV001715794 | uncertain significance | not provided | 2020-10-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001509204 | SCV001982728 | uncertain significance | not provided | 2024-06-28 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34426522, 31734026) |
Ambry Genetics | RCV002454029 | SCV002616716 | uncertain significance | Inborn genetic diseases | 2018-06-12 | criteria provided, single submitter | clinical testing | The p.R1190C variant (also known as c.3568C>T), located in coding exon 34 of the KIF1A gene, results from a C to T substitution at nucleotide position 3568. The arginine at codon 1190 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Athena Diagnostics | RCV004997438 | SCV005622306 | likely benign | not specified | 2023-12-15 | criteria provided, single submitter | clinical testing |